OTS HPV vaccine / Black Canyon Bio - LARVOL DELTA

Accelerating precision immunotherapy for HPV-driven cancers (AACR 2026) - "This study covers the development of the OTS HPV vaccine. The OTS vaccine is a poly-epitope construct targeting conserved HPV16 oncoproteins E6, E7, and E2, plus recurrent PIK3CA hotspot mutations (detected in >40% of HPV+ cancers), Candidate OTS peptides underwent comprehensive in silico predictive modeling... This project will deliver a clinically actionable off-the-shelf vaccine platform that enables early immunologic intervention in HPV16-driven cancers. By priming the immune system ahead of personalized therapy, we aim to reduce time-to-treatment, enhance therapeutic outcomes, and expand access to precision immunotherapy."

IO biomarker • Oncology • Oropharyngeal Cancer • IFNG • PIK3CA